Blog posts for patients and caregivers who are interested in Kloxxado® (naloxone HCl) Nasal Spray 8 mg.
It’s estimated that five to eight million Americans use opioids to manage chronic pain (i.e., pain lasting longer than three months).1,2 Opioids are also used for acute pain, cancer-related [...]
One Spray Could Save a Life US Drug Enforcement Administration (DEA) officials and college administrators across the country issued a warning to students headed off to college this past [...]
Did you know that more than half of adults aged 65 and older take 4 or more prescription drugs? For many, it’s because they’re managing conditions like high blood [...]
The shelf-life of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg has been extended to 36 months. Find out why this is important for first responders and others who carry naloxone.
Naloxone is a life-saving medicine that can be used to quickly reverse opioid overdose. Read on to learn more about intranasal naloxone and how it works.
Kloxxado® (naloxone HCl) Nasal Spray 8 mg, a new opioid overdose reversal medication, is FDA approved. Approval is granted in view of opioid overdose deaths reaching an all-time high.
What is KLOXXADO® Nasal Spray?
What is the most important information I should know about KLOXXADO® Nasal Spray?
Get emergency medical help right away after giving the first dose of KLOXXADO® Nasal Spray. The signs and symptoms of an opioid emergency can return after KLOXXADO® Nasal Spray is given. If this happens, give another dose after 2 to 3 minutes using a new KLOXXADO® Nasal Spray and watch the person closely until emergency help is received.
The medicine in KLOXXADO® Nasal Spray is safe to use in people who are not taking opioids. KLOXXADO® Nasal Spray is not intended for self-administration.
What should I tell my healthcare provider (pharmacist or prescriber) before using?
Before using KLOXXADO® Nasal Spray, tell your healthcare provider about all of your medical conditions, including if you:
What are the possible serious side effects of KLOXXADO® Nasal Spray?
KLOXXADO® Nasal Spray may cause sudden opioid withdrawal symptoms including body aches, diarrhea, increased heart rate, fever, runny nose, sneezing, goose bumps, sweating, yawning, nausea or vomiting, nervousness, restlessness or irritability, shivering or trembling, stomach cramping, weakness, and increased blood pressure.
In infants under 4 weeks old who have been receiving opioids regularly, sudden opioid withdrawal may be life-threatening if not treated the right way. Signs and symptoms include seizures, crying more than usual, and increased reflexes.
Who should not use KLOXXADO® Nasal Spray?
Do not use KLOXXADO® Nasal Spray if you are allergic to naloxone hydrochloride or any of the ingredients in KLOXXADO® Nasal Spray.
What are the most common side effects of KLOXXADO® nasal spray?
The most common side effects of KLOXXADO® Nasal Spray in adults include stomach-area (abdomen) pain, weakness, dizziness, headache, nose (nasal) discomfort, and a feeling like you are going to faint.
These are not all of the possible side effects of KLOXXADO® Nasal Spray. Please click here for the accompanying full Prescribing Information, including Patient Information, which includes a more complete discussion of the risks associated with KLOXXADO® Nasal Spray. Always contact your healthcare provider (pharmacist or prescriber) if you have questions or experience any side effects.
You are encouraged to report negative side effects to the FDA at: 1-800-FDA-1088 or www.fda.gov/medwatch. You can also contact Hikma Specialty USA Inc. at: [email protected] or call 1-877-845-0689 or 1-800-962-8364.
Tell Us About a Side Effect
1-877-845-0689 or 1-800-962-8364 | Email
Contact Customer Service
1-844-462-7226 | Email
This website is intended for U.S. audiences
© Hikma Pharmaceuticals USA Inc. All rights reserved.
KLOXXADO®️ is a registered trademark of Hikma Pharmaceuticals USA Inc.
Emergent Devices Inc. is wholly owned subsidiary of Emergent BioSolutions Inc.
KLOXXADO®️ is manufactured by Hikma Pharmaceuticals USA Inc. Columbus, OH 43228, and distributed by Emergent Devices Inc. Plymouth Meeting, PA 19462.
PP-KLOX-US-00040
February 2026